Recent advances in the management of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Several histamine H2 receptor antagonists and the H+,K(+)-ATPase inhibitor, omeprazole, have been shown to be capable of controlling gastric acid secretion safely and effectively in patients with Zollinger-Ellison syndrome. The relative merits of these agents are discussed, and their use in the acute and long-term control of acid hypersecretion and in special circumstances that require particular care are described. The surgical approaches to the control of acid secretion are described, and the current place of surgery in the management of acid hypersecretion is discussed.
Maton
P N
PN
Digestive Diseases Branch, National Institute of Diabetes, and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Gardner
J D
JD
Jensen
R T
RT
D002927:Cimetidine / Q000627:therapeutic use; D015738:Famotidine / Q000627:therapeutic use; D005744:Gastric Acid / Q000378:metabolism*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D016567:Nizatidine; D009853:Omeprazole / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D011899:Ranitidine / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use; D015043:Zollinger-Ellison Syndrome / Q000150:complications / Q000188:drug therapy* / Q000628:therapy
D006635:Histamine H2 Antagonists; D010276:Parasympatholytics; D013844:Thiazoles; D015738:Famotidine; D002927:Cimetidine; D011899:Ranitidine; D009853:Omeprazole; D016567:Nizatidine